Caribou Biosciences (CRBU) Current Deferred Revenue: 2020-2025
Historic Current Deferred Revenue for Caribou Biosciences (CRBU) over the last 5 years, with Sep 2025 value amounting to $4.0 million.
- Caribou Biosciences' Current Deferred Revenue fell 41.37% to $4.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.0 million, marking a year-over-year decrease of 41.37%. This contributed to the annual value of $6.4 million for FY2024, which is 27.97% down from last year.
- Per Caribou Biosciences' latest filing, its Current Deferred Revenue stood at $4.0 million for Q3 2025, which was down 13.65% from $4.6 million recorded in Q2 2025.
- Caribou Biosciences' 5-year Current Deferred Revenue high stood at $31.1 million for Q2 2023, and its period low was $4.0 million during Q3 2025.
- In the last 3 years, Caribou Biosciences' Current Deferred Revenue had a median value of $7.4 million in 2024 and averaged $10.7 million.
- As far as peak fluctuations go, Caribou Biosciences' Current Deferred Revenue soared by 18,990.06% in 2021, and later slumped by 76.12% in 2024.
- Quarterly analysis of 5 years shows Caribou Biosciences' Current Deferred Revenue stood at $30.7 million in 2021, then fell by 15.76% to $25.9 million in 2022, then plummeted by 65.44% to $8.9 million in 2023, then fell by 27.97% to $6.4 million in 2024, then plummeted by 41.37% to $4.0 million in 2025.
- Its last three reported values are $4.0 million in Q3 2025, $4.6 million for Q2 2025, and $5.5 million during Q1 2025.